Today, FDA granted approval to Tudriqev, a genetically modified oncolytic viral therapy, used with nivolumab, for adults with resistant advanced melanoma. This

Today, FDA granted approval to Tudriqev, a genetically modified oncolytic viral therapy, used with nivolumab, for adults with resistant advanced melanoma. This approval underscores FDA’s commitment to using every available regulatory tool to help bring meaningful treatment options to patients with s…